Concept information
Terme préférentiel
Natalizumab
Type
-
mesh:Descriptor
Définition
- A humanized monoclonal immunoglobulin G4 antibody to human INTEGRIN ALPHA4 that binds to the alpha4 subunit of INTEGRIN ALPHA4BETA1 and integrin alpha4beta7. It is used as an IMMUNOLOGIC FACTOR in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS and CROHN'S DISEASE.
Concept générique
Qualificatif(s) autorisé(s)
- administration & dosage (Qualifier)
- adverse effects (Qualifier)
- analysis (Qualifier)
- biosynthesis (Qualifier)
- blood (Qualifier)
- cerebrospinal fluid (Qualifier)
- chemistry (Qualifier)
- classification (Qualifier)
- drug effects (Qualifier)
- economics (Qualifier)
- genetics (Qualifier)
- history (Qualifier)
- immunology (Qualifier)
- isolation & purification (Qualifier)
- metabolism (Qualifier)
- pharmacokinetics (Qualifier)
- pharmacology (Qualifier)
- physiology (Qualifier)
- poisoning (Qualifier)
- radiation effects (Qualifier)
- therapeutic use (Qualifier)
- toxicity (Qualifier)
- ultrastructure (Qualifier)
- urine (Qualifier)
Action(s) pharmacologique(s)
Traductions
-
français
URI
http://data.loterre.fr/ark:/67375/JVR-XKMPTSNG-4
{{label}}
{{#each values }} {{! loop through ConceptPropertyValue objects }}
{{#if prefLabel }}
{{/if}}
{{/each}}
{{#if notation }}{{ notation }} {{/if}}{{ prefLabel }}
{{#ifDifferentLabelLang lang }} ({{ lang }}){{/ifDifferentLabelLang}}
{{#if vocabName }}
{{ vocabName }}
{{/if}}